Read about various aspects of career trajectories in oncology from the perspective of established clinicians, new attendings, and those waiting to sit for their medical board exams.
Multiple mutations and gene alterations make targeted therapy development more difficult for patients with AML, according to Amir Fathi, MD.
Date: June 24th, 2025 Time: 12:00 – 1:00 pm EST Location: Zoom Presentation Title: Use of Simulation to Educate Fellows on CAR T-cell Therapy Speakers:…
Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.
Panelists discuss how patients have been receptive to the proactive management approach that effectively reduces dermatologic adverse effects, despite initial concerns about adding multiple prophylactic…
Daniel Kim, MD, MBA discusses how genomic testing has revolutionized patient selection for active surveillance by integrating molecular insights that transcend traditional clinical parameters, enabling…
BGB-16673 antitumor activity occurred particularly among patients with BTK-resistant mutations and those refractory to prior cBTK and ncBTK inhibition.
First-line systemic therapy plus radiation therapy improved PFS vs second-line systemic therapy with or without radiation in hepatocellular carcinoma.
Bexobrutideg, a novel BTK degrader, demonstrated preliminary clinical activity and a consistent safety profile in patients with relapsed/refractory chronic lymphocytic leukemia.
Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic…
Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.
